Grant Funding Opportunities

Vantive is interested in funding research that advances knowledge of Acute Digital Health, Broad-spectrum hemadsorption with Oxiris, Continuous Renal Replacement Therapy (CRRT) and Acute Kidney Injury (AKI), Extracorporeal CO2 Removal (ECCO₂R) and PrismaLung+. Within each of these areas of focus, targeted research topics include clinical effectiveness, workflow and therapy optimization, patient safety, health-economic impact, and technology-enabled innovations. These priority topics are detailed in the Investigator Initiated Research application form but summarized below.

Research priorities include validating and implementing digital health tools to improve extracorporeal therapy delivery, clinical workflows, patient safety, and health-economic outcomes. Key focuses for Oxiris hemoadsorption include assessing biological and clinical effectiveness, treatment timing, patient phenotypes, non-infectious inflammatory conditions, digital decision-support applications, large-dataset analyses, and quality-of-life and economic impact. 

Priorities in CRRT and AKI center on clinical and economic outcomes across specific populations, long-term kidney health, utilization patterns, and the influence of education and care models, as well as scenario-specific outcomes such as fluid overload and hemodynamic instability.

For ECCO₂R and PrismaLung+, research includes short- and long-term clinical outcomes across respiratory failure types, inflammatory and organ-interaction effects, combined CRRT–ECCO₂R therapy, anticoagulation optimization, quality metrics, and cost-effectiveness relative to other lung-support strategies.

CRRT

• Acute kidney Injury: disease, diagnosis, and management
• Continuous renal replacement therapy (CRRT): prescription and practices
• CRRT in the management of specific AKI scenarios (e.g., fluid overload, hemodynamic instability, CSA-AKI, post-operative AKI, multiple organ dysfunction)
• Regional citrate anticoagulation for CRRT
• CRRT quality improvement programs and therapy adoption

Blood purification

• Application and outcome of blood purification in different patient populations including sepsis and septic shock
• Biological, physiological, and clinical effects of blood purification technology with Oxiris
• Utilization of different biomarkers to guide and monitor blood purification. + Timing and stratification of treatment
• Identifying different phenotypes, endotypes and genotypes in sepsis and their potential response to blood purification/adsorption
• Outcomes in other patient conditions characterized by non-infectious inflammatory process through hemadsorption (i.e.: reduction of CSA-AKI, cytokine removal (cart t cells), burns)
• Application of Oxiris to reduce effects of extracorporeal circuits (e.g. CPB in cardiac surgery).
• Application of digital technology for support in blood purification (e.g. decision support, digital twins) and in sillico studies based on the analysis of large data sets (e.g. registry data).  
• Improvement of long term outcome and quality of life with Oxiris treatment.
• Effects of ECCO2R on different variables of ventilation (e.g. Ventilatory ratio, mechanical energy, biomarker) to identify optimal patients for ECCO2R and demonstrate effectiveness.
• Short and long term outcome of ECCO2R in different forms of lung failure, including ARDS and aeCOPD.
• Impact of different technologies on outcome of ECCO2R
• ECCO2R quality improvement ( management of anti-coagulation and circuits).
• Effects of ECCO2R on inflammatory interaction and organ cross talk (e.g. pulmonary / renal interactions).
• Short and long term of CRRT & ECCO2R combination.
• Cost effectiveness of ECCO2R vs other forms of extracorporeal lung support.

Vantive aims to support high-quality clinical and health-economic research that strengthens the evidence base for its peritoneal dialysis (PD) therapies. Priority areas include improving access to PD by addressing barriers and understanding drivers of therapy selection and uptake; evaluating the role of digital health technologies, such as remote patient monitoring, in enhancing PD delivery and clinical workflows; and generating evidence on PD patient outcomes, particularly healthcare resource utilization and time on therapy. Additional research seeks to advance understanding of chronic kidney disease (CKD) progression and management to optimize therapy selection and support effective patient onboarding.

In 2026, medical education will center on improving outcomes in peritoneal dialysis (PD) therapy through a comprehensive approach that strengthens clinicians’ knowledge and application of best practices across the full PD continuum. Educational efforts will emphasize modality education to support informed therapy selection, reinforce the importance of an optimal start to PD to enhance patient stability and long-term success, and deepen clinical proficiency in PD catheter insertion and evidence-based PD prescribing. Additionally, programming will focus on practical strategies for integrating these practices seamlessly into clinical workflows, enabling care teams to deliver consistent, high-quality PD therapy that drives better patient outcomes and supports broader adoption of home-based renal replacement therapies.